Literature DB >> 8091386

Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor.

A Ceriello1, M Pirisi, R Giacomello, G Stel, E Falleti, E Motz, S Lizzio, F Gonano, E Bartoli.   

Abstract

Fibrinogen has recently emerged as a major risk factor for atherothrombosis. However, the pathophysiologic mechanism linking high fibrinogen concentration to cardiovascular disease is unclear. In this study 136 subjects (75 males, 61 females, age 51.7 +/- 14.4 years, mean +/- standard deviation, range 17-82) were tested for total and HDL-cholesterol, total triglycerides, apolipoprotein AI, apolipoprotein B, fibrinogen, prothrombin fragment and D-dimer. Moreover, 5 subjects who had hyperfibrinogenemia (range 450 to 950 mg/dl) for at least 6 months by repeated measurements, were treated with a short 7-day course of heparin 12,500 U/day subcutaneously. The effect of heparin on all the above mentioned parameters was observed at the end of treatment and after 7 days of wash-out. Simple regression analysis detected a positive correlation between fibrinogen and age, prothrombin fragment and D-dimer, and a negative correlation between fibrinogen and HDL-cholesterol and apolipoprotein AI. A direct correlation between age and both prothrombin fragment and D-dimer was also demonstrated. Multivariate analysis showed a persistent correlation between fibrinogen and prothrombin fragment, D-dimer and age, that was not influenced by sex, smoking habit and body mass index. In the 5 hyperfibrinogenemic subjects, heparin administration significantly reduced fibrinogen (625.4 +/- 211.1 vs 455.2 +/- 112.3 mg/dl, p < 0.03), prothrombin fragment (0.97 +/- 0.1 vs 0.63 +/- 0.2 nM, p < 0.002) and D-dimer (336 +/- 101.8 vs 275.2 +/- 78.5 ng/ml, p < 0.03). All these parameters returned to baseline after 7 days of wash-out (fibrinogen 632.5 +/- 198.2 mg/dl, prothrombin fragment 0.96 +/- 0.2 nM, D-dimer 325.8 +/- 98.65 ng/ml).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8091386

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Antithrombotic treatment in stable coronary syndromes: long-term intermittent urokinase therapy in end-stage coronary artery disease and refractory angina pectoris.

Authors:  F C Schoebel; T W Jax; Y Fischer; B E Strauer; M Leschke
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

2.  Variations and clinical significance of coagulation and fibrinolysis parameters in patients with diabetes mellitus.

Authors:  J Hu; W Wei; G Din; L Yuan; Z Liu
Journal:  J Tongji Med Univ       Date:  1998

3.  Post-meal coagulation activation in diabetes mellitus: the effect of acarbose.

Authors:  A Ceriello; C Taboga; L Tonutti; R Giacomello; L Stel; E Motz; M Pirisi
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

Review 4.  New approaches to the prevention of atherosclerosis.

Authors:  M Naito; T Hayashi; A Iguchi
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

5.  Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case-control study using quantitative coronary angiography.

Authors:  F C Schoebel; F Gradaus; K Ivens; P Heering; T W Jax; B Grabensee; B E Strauer; M Leschke
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

6.  The Difference Quantity of Urinary Peptides between Two Groups of Type 2 Diabetic Patients with or without Coronary Artery Disease.

Authors:  Guangzhen Fu; Mei Hu; Lina Chu; Man Zhang
Journal:  Int J Endocrinol       Date:  2015-05-18       Impact factor: 3.257

7.  Two urinary peptides associated closely with type 2 diabetes mellitus.

Authors:  Man Zhang; Guangzhen Fu; Ting Lei
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.